GenEdit Inc.

With the business year almost complete, a review of biopharmaceutical dealmaking showed that Novartis, in particular, enjoyed a very productive year with 21 transactions overall, including six acquisi

Who: Genentech/COUR Pharmaceuticals What: Roche subsidiary Genentech entered into a collaboration and licensing agreement with COUR Pharmaceuticals to develop and commercialize COUR’s tolerogenic n

Ascendis Pharma A/S has two approved products and plans to submit a third drug candidate for approval later this year from its endocrinology rare disease portfolio. It also has two clinical-stage can

Who: Roche Holding AG ’s Genentech, Inc. / GenEdit Inc. What: Genentech will partner with GenEdit to discover hydrophilic nanoparticles for the development of nucleic acid-based medicines for au